By crossing the high, low or negative TRPML1 and TRPML2 mRNA expressions evaluated simultaneously in each GBM specimen, out of the potential nine subgroups, no TRPML2neg TRPML1high, TRPML2low TRPML1low and TRPML2low TRPML1neg subgroups were found on the 66 GBM patients analyzed. This evidence concerns the gene MCOLN2 and glioblastoma.